Therefore, to answer this question and by leveraging our knowledge of prostate cancer, where androgen deprivation therapy plus androgen receptor pathway inhibitors can be combined with docetaxel, we believe that a cohort of patients with IHC-LAR in a potential umbrella trial for intrinsic subtypes of TNBC should be considered to receive adjuvant capecitabine plus ARPI [26]. The gene discussed is AR; the disease is prostate carcinoma.